Skip to main content
    E

    Evolent Health Inc (EVH)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NYSE

    $4.83
    -0.07 (-1.53%)

    Market Cap: $554.22M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Evolent Health Inc (EVH) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Evolent Health reported revenue of $1.88B for the fiscal year ended Dec 31, 2025, down 26.6% from the year before. That year, net income was -$534.51M with a net margin of -28.5%, operating cash flow was $38.84M and free cash flow was $4.75M. The quarter ended Sep 30, 2026 had revenue of $725.37M and net income of -$23.57M.

    Revenue and Margins

    The operating margin was -21.9% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $254.19M, a compound annual rate of 24.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.88B-26.6%21.3%-21.9%-28.5%
    Dec 2024$2.55B+30.1%14.4%-1.6%-2.4%
    Dec 2023$1.96B+45.3%23.4%-3.6%-5.8%
    Dec 2022$1.35B+48.9%23.4%0.3%-1.4%
    Dec 2021$907.96M-1.8%27.6%-4.7%-4.1%
    Dec 2020$924.64M+34.6%100.0%-28.4%-36.1%
    Dec 2019$687.12M+9.6%100.0%-45.0%-44.5%
    Dec 2018$627.06M+44.2%100.0%-7.6%-8.6%
    Dec 2017$434.95M+71.1%100.0%-16.7%-16.0%
    Dec 2016$254.19MN/A100.0%-93.4%-89.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$1.88B$2.55B$1.96B$1.35B$907.96M$924.64M$687.12M$627.06M$434.95M$254.19M
    Cost of revenue$1.48B$2.19B$1.50B$1.04B$657.55M$0$0$0$0$0
    Gross profit$399.88M$367.35M$460.47M$316.58M$250.41M$924.64M$687.12M$627.06M$434.95M$254.19M
    Operating income-$410.14M-$40.48M-$71.21M$3.64M-$42.41M-$262.85M-$308.88M-$47.48M-$72.84M-$237.42M
    Net income-$534.51M-$61.62M-$113.04M-$19.16M-$37.60M-$334.25M-$305.58M-$54.19M-$69.77M-$226.78M
    EBITDA-$332.79M$86.30M$4.43M$50.30M$48.57M-$165.51M-$233.37M$2.19M-$39.56M-$220.19M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$725.37M$652.52M$496.25M$468.72M$479.53M$444.33M$483.65M$646.54M$621.40M$647.14M$639.65M$556.05M
    Gross profit$88.42M$80.84M$83.77M$97.25M$99.77M$100.39M$102.47M$75.71M$80.69M$106.84M$104.11M$101.63M
    Operating income-$6.19M-$9.56M-$10.60M-$408.23M$886.00K-$1.17M-$1.62M-$18.60M-$16.27M$7.79M-$13.41M-$21.35M
    Net income-$23.57M-$28.36M-$26.63M-$429.13M-$20.86M-$19.90M-$64.62M-$22.80M-$23.14M$1.60M-$17.28M-$33.41M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $985.88M exceeded cash and equivalents by $834.02M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.90B$2.54B$2.68B$1.82B$1.42B$1.37B$1.50B$1.72B$1.31B$1.20B
    Current assets$506.37M$607.12M$683.67M$478.05M$523.96M$547.65M$228.80M$487.97M$378.18M$264.97M
    Cash and equivalents$151.86M$104.20M$192.82M$188.20M$266.28M$319.00M$101.01M$228.32M$238.43M$134.56M
    Total liabilities$1.48B$1.35B$1.43B$957.88M$725.83M$752.10M$568.97M$532.92M$266.39M$287.73M
    Short-term debt$15.34M$171.47M$0$7.12M$7.07M$26.56M$0$122.60M$121.39M$120.28M
    Long-term debt$970.54M$490.52M$597.05M$412.99M$215.68M$263.34M$293.67M$221.04M$121.39M$120.28M
    Shareholder equity$415.19M$1.00B$1.07B$859.42M$693.63M$619.60M$922.36M$1.14B$1.01B$702.53M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.96B$1.97B$1.88B$1.90B$2.45B$2.46B$2.65B$2.54B$2.50B$2.48B$2.64B$2.68B
    Total liabilities$1.59B$1.59B$1.48B$1.48B$1.61B$1.34B$1.52B$1.54B$1.28B$1.24B$1.41B$1.61B
    Cash and equivalents$148.25M$115.70M$142.03M$151.86M$116.65M$151.00M$246.55M$104.20M$96.58M$101.25M$165.15M$192.82M
    Shareholder equity$372.85M$383.22M$396.39M$415.19M$842.23M$896.00M$935.52M$1.00B$1.04B$1.05B$1.05B$1.07B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 12.2% of operating cash flow. Dividends and share repurchases together came to 1076.2% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$38.84M$18.77M$142.58M-$11.55M$38.75M-$16.23M-$42.65M-$20.65M-$27.96M-$35.51M
    Capital expenditures$34.09M$24.89M$28.75M$38.36M$24.98M$29.47M$35.53M$39.55M$27.85M$15.53M
    Free cash flow$4.75M-$6.13M$113.84M-$49.91M$13.76M-$45.70M-$78.18M-$60.20M-$55.81M-$51.04M
    Dividends paid$11.13M$20.09M$18.79M$14.88M$1.30M$20.00M$0$0$0$0
    Share repurchases$40.00M$0$0N/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$233.00K-$62.93M-$415.54M-$259.12M-$15.79M$261.07M-$181.63M-$160.38M-$12.27M-$96.66M
    Financing cash flow-$35.92M-$565.00K$281.34M$131.54M-$29.55M-$11.86M-$35.55M$274.02M$165.56M$150.19M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$26.38M-$9.31M-$984.00K$48.80M$15.81M-$30.33M$4.57M-$26.23M$18.67M$21.42M$4.91M$89.38M
    Capital expenditures$7.21M$6.85M$6.41M$7.76M$8.96M$8.77M$8.60M$6.15M$6.29M$7.11M$5.35M$6.05M
    Free cash flow$19.17M-$16.16M-$7.39M$41.04M$6.85M-$39.10M-$4.03M-$32.38M$12.38M$14.31M-$438.00K$83.33M
    Last 12 quarters

    Frequently Asked Questions About EVH

    What is Evolent Health's annual revenue?

    Evolent Health reported revenue of $1.88B for the fiscal year ended Dec 31, 2025.

    How fast is Evolent Health's revenue growing?

    Revenue was down 26.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 11.5%.

    Is Evolent Health profitable?

    No. Evolent Health reported net income of -$534.51M for the fiscal year ended Dec 31, 2025, with a net margin of -28.5%.

    How much free cash flow does EVH generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $38.84M minus capital expenditures of $34.09M produced free cash flow of $4.75M.

    How much debt does Evolent Health have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $970.54M, short-term debt of $15.34M and cash and equivalents of $151.86M.